135 results on '"Garau, I."'
Search Results
2. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade
3. Attenuation of the epidemic increase in non-Hodgkin's lymphomas in Spain
4. Actitudes de los trabajadores frente a los programas de promoción de la salud para la prevención del cáncer en el lugar del trabajo
5. Comparability of colorectal cancer survival data in three European population-based registries
6. Independència de la deambulació i la defecació en un camp obert poc atemoridor, posada de manifest en un estudi generacional
7. Characteristics of HR+/HER2-patients with recurrent disease from a prospective registry of unresectable locally advanced or metastatic breast cancer: GEICAM/2014-03 (RegistEM)
8. A multicenter, randomized, phase II trial evaluating the efficacy of eribulin monotherapy and eribulin plus endocrine therapy in locally-recurrent or metastatic breast cancer patients after progression on endocrine therapy (REVERT study)
9. Independència de la deambulació i la defecació en un camp obert poc atemoridor, posada de manifest en un estudi generacional
10. Importància de la recerca amb models animals en el camp de les diferències individuals
11. Extraversió humana i deambulació en rates
12. Investigació en Psicologia experimental i Psicofisiologia a la Secció de Psicologia de la Universitat Autònoma de Barcelona (1979-1983)
13. The ERα/ERβ ratio determines oxidative status in postmenopausal women mammary carcinomas: P08-18
14. Abstract P6-17-08: Dynamics of tumor-infiltrating lymphocytes (TILs) during neoadjuvant dual HER2 blockade in HER2-positive (HER2+) breast cancer in the absence of chemotherapy
15. Abstract P6-17-07: Gene signatures and subtype changes during HER2 dual blockade in PAM50 HER2-enriched HER2-positive breast cancer
16. Psychological impact of multigene cancer panel testing in patients with a clinical suspicion of hereditary cancer across Spain
17. Abstract P2-09-14: A predictive model of pathological response following dual HER2 blockade-only based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer
18. Abstract P5-20-19: PAM50 intrinsic subtype predicts survival outcome in HER2-positive/hormone receptor-positive metastatic breast cancer treated with palbociclib and trastuzumab: a correlative analysis of the PATRICIA (SOLTI 13-03) trial
19. Incidencia y mortalidad por cáncer en España. Patrones y tendencia
20. SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (with or without letrozole in ER+) in previously trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer
21. Tumor-infiltrating lymphocytes (TILs) in HER2-positive (HER2+) early breast cancer treated with neoadjuvant lapatinib and trastuzumab without chemotherapy in the PAMELA Trial
22. Abstract OT3-02-07: A phase II study to compare fulvestrant (F) 500mg plus placebo versus (vs) F 500mg plus palbociclib (P) as first line treatment for postmenopausal women with hormone receptor (HR)-positive advanced breast cancer (BC) sensitive to endocrine therapy (ET). “The FLIPPER study” (GEICAM/2014-12)
23. Abstract P5-15-18: MERIBEL STUDY: Single-agent eribulin as first-line therapy for taxane-resistant HER2[-] metastatic breast cancer (MBC) patients (pts)
24. Abstract P6-09-33: CASCADE study: Rapid survival decline per treatment line in metastatic breast cancer
25. Childhood cancer survival in Europe
26. EUROCARE-3: survival of cancer patients diagnosed 1990–94—results and commentary
27. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century
28. Influence of stage at diagnosis on survival differences for rectal cancer in three European populations
29. MERIBEL study: Single-agent eribulin as first-line therapy for taxane-resistant HER2[-] metastatic breast cancer (MBC) patients (pts)
30. Famosa: Evaluation of a multigene panel in patients with suspected HBOC
31. CASCADE study: pronounced decline in treatment efficacy through the metastatic life of breast cancer patients
32. Abstract P3-07-39: CASCADE study: Treatment and clinical outcomes of metastatic breast cancer by tumor immunophenotypes
33. Abstract P5-08-43: CASCADE study: Longer overall survival inthe novoversus recidivant patients with locally advanced/metastatic breast cancer
34. Burden Of Advanced Breast Cancer For Patients And Caregiver In Europe: Comparisons Of Two Treatment Forms Of Vinorelbine, Oral And Intravenous
35. 1882 CASCADE study: Epidemiological analysis of current natural history and treatment patterns of metastatic breast cancer in spain
36. Brio: A European Prospective Observational Study to Assess the Burden of Disease and Treatment in Metastatic Breast Cancer (Mbc) Patients Treated with Oral Vinorelbine (Nvboral) or Intravenous Vinorelbine (Ivvino)
37. Adesione alle linee guida per il trattamento dei carcinomi della mammella a stadio limitato in relazione alla spesa sanitaria nazionale totale
38. Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States
39. 321TiP - SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (with or without letrozole in ER+) in previously trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer
40. 155PD - Tumor-infiltrating lymphocytes (TILs) in HER2-positive (HER2+) early breast cancer treated with neoadjuvant lapatinib and trastuzumab without chemotherapy in the PAMELA Trial
41. Compliance with good practice in early breast cancer treatment in relation to total national health expenditure
42. Trends in cervical cancer survival in Europe, 1983-1994: a population-based study
43. Indicators od compliance with guidelines in the EUROCARE-3 High Resolution study on breast cancer
44. Survival from rare cancer in adults: a population-based study
45. The EUROCARE-3 database: methodology of data collection, standardisation, quality control and statistical analysis
46. Actitudes de los trabajadores frente a los programas de promoción de la salud para la prevención del cáncer en el lugar del trabajo
47. Els fars de Catalunya
48. Cancer incidence and mortality in Spain. Patterns and trends
49. 248P - CASCADE study: pronounced decline in treatment efficacy through the metastatic life of breast cancer patients
50. 238P - MERIBEL study: Single-agent eribulin as first-line therapy for taxane-resistant HER2[-] metastatic breast cancer (MBC) patients (pts)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.